Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

OncoSec Medical, Inc. (ONCS) Announces Patient Enrollment And Screening Sites For Phase II Melanoma Clinical Trial

|Includes: OncoSec Medical Incorporated (ONCS)

OncoSec Medical, a biopharm company developing its advanced-stage OMS ElectroOncology therapies for the treatment of solid tumor cancers and metastatic disease, today announced it has initiated the John Wayne Cancer Institute in Santa Monica, Calif., and Lakeland Comprehensive Cancer Center in Lakeland, Fla., as patient enrollment and screening sites for its phase II metastatic melanoma clinical trial (OMS-1100) for the company's OMS Electro Immunotherapy treatment.

OncoSec Medical plans to enroll 25 patients with stage III or IV cutaneous and in-transit metastatic melanoma. Patients will receive one treatment cycle with three treatments applied to up to four lesions on days one, five, and eight. At 12 months, patients will be moved to the follow-up phase of the study and will be followed for up to five years for safety.

"We are very pleased to have two respected investigators in melanoma clinical research, Drs. Mark Faries and Manuel Molina joining our phase II clinical study," Punit Dhillon, OncoSec Medical's president and CEO stated in the press release. "Both the John Wayne Cancer Institute and Lakeland Comprehensive Cancer Center are state of the art clinical sites and represent important centers of excellence that will add value to enrollment targets and expertise by participating in the study."

Dr. Faries, principal investigator at John Wayne Cancer Institute, noted the ease of which the ElectroImmunotherapy treatment is administered, as well as the therapy's potential as an alternative therapy.

Dr. Molina, principal investigator at Lakeland Comprehensive Cancer Center, recapped the phase I study, which demonstrated the therapy as safe and with "durable therapeutic benefit." OMS ElectroImmunotherapy was demonstrated as safe and well-tolerated. Additionally, 53 percent of patients with distant metastatic lesions demonstrated an objective response, with 15 percent of these patients having a complete response to the treatment.

"Advancing into a phase II study is encouraging and is important for validation of results seen in the phase I study. We look forward to participating in this trial," Dr. Molina stated.

Please see disclaimer on the QualityStocks website: